ライフサイエンスコーパス: NSTEMI

1 NSTEMI patients were older (60.3 years vs 57.7 years, p

2 NSTEMI patients were older and had a higher rate of medi

3 We reassessed 10 NSTEMI and 10 SA patients after 1 year.

4 From October, 2009, to November, 2011, NSTEMI patients were assigned oral losmapimod (7.5 mg or

5 abetes (22.8%-28.3% [STEMI] and 35.7%-41.3% [NSTEMI]) and atrial fibrillation (4.1%-6.1% and 9.4%-11.

6 sented as chronic coronary syndrome (43.3%), NSTEMI (36.7%), and unstable angina (20%).

7 rvention were included: 50 stable angina, 50 NSTEMI, and 40 STEMI.

8 We included 11543 STEMI and 8470 NSTEMI patients who underwent PCI in the Singapore Myoca

9 a primary diagnosis of first-time MI (54.9% NSTEMI and 45.1% STEMI).

10 yzed data including 72 352 patients (48 966, NSTEMI; 23 386, STEMI) from 237 US sites between May 1,

11 nts (27.2%) in the observe-zone (adjudicated NSTEMI prevalence, 120/564 patients, 21.3%).

12 , 22.5%, versus men, 14.9%) as well as after NSTEMI (women, 23.2%, versus men, 15.7%).

13 predictors of spontaneous MI were older age, NSTEMI versus UA as index event, diabetes mellitus, no p

14 Among NSTEMI patients with frailty, 14,414 patients (54.3%) un

15 a nationwide sample of STEMI (n=19 029) and NSTEMI (n=30 462) patients.

16 l or minimal angiographic disease (n=23) and NSTEMI (n=24), intravascular ultrasound-derived measures

17 20; percent reduction 21%, 95% CI 12-29) and NSTEMI (383 PCI procedures per week in 2019 vs 240 by th

18 ailty (Clinical Frailty Scale score >=4) and NSTEMI.

19 ailty (Clinical Frailty Scale score >=4) and NSTEMI.

20 serve ratio was similar in stable angina and NSTEMI patients (P=0.6).

21 = 256 culprit-only vs n = 253 complete) and NSTEMI (n = 469 culprit-only vs n = 467 complete).

22 clinical trial of patients with frailty and NSTEMI, an invasive treatment strategy did not improve o

23 ommended for older patients with frailty and NSTEMI.

24 CT After STEMI [ST-segment elevation MI] and NSTEMI [non-STEMI] in Patients With Residual Non-flow Li

25 higher pre-PCI in STEMI compared with SA and NSTEMI (IMR STEMI, 36.51 versus IMR NSTEMI, 22.73 [P=0.0

26 Hospitalization rates for STEMI and NSTEMI decreased between 2011 and 2018 in all countries,

27 modified SMIR risk score for both STEMI and NSTEMI patients and compared its performance to the GRAC

28 in a multi-ethnic Asian cohort of STEMI and NSTEMI patients and report increased risk of recurrent M

29 ial (Bivalirudin Versus Heparin in STEMI and NSTEMI Patients on Modern Antiplatelet Therapy-Swedish W

30 MI within 1 year after PCI in both STEMI and NSTEMI patients, there was no increase in mortality.

31 for cardiovascular events in both STEMI and NSTEMI patients.

32 ck status of 235 541 patients with STEMI and NSTEMI treated at 392 US hospitals from 2007 to 2011.

33 coronary syndrome, including both STEMI and NSTEMI, but relative and absolute reductions were larger

34 , 30.5% and 42.9% of patients with STEMI and NSTEMI, respectively, had CKD.

35 P<0.001 for all) in patients with STEMI and NSTEMI, respectively.

36 th high mortality in patients with STEMI and NSTEMI.

37 py was high for patients with both STEMI and NSTEMI.

38 spectrum of myocardial infarction, STEMI and NSTEMI.

39 better clinical outcomes following STEMI and NSTEMI.

40 comes were assessed separately for STEMI and NSTEMI.

41 sed considerably for patients with STEMI and NSTEMI.

42 elevation myocardial infarction (STEMI) and NSTEMI (56% vs. 44%).

43 The association between AF and MI, total and NSTEMI, was stronger in women than in men (P for interac

44 mbines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT 5 trial.

45 vasive management among patients with UA and NSTEMI, in the context of contemporary medical therapy,

46 ve heart failure) among patients with UA and NSTEMI.

47 proving clinical outcomes in unstable angina/NSTEMI patients has led to investigations of its role in

48 e and quality measures were compared between NSTEMI and STEMI patients.

49 ignificant difference in IMR pre-PCI between NSTEMI and SA (IMR NSTEMI, 22.73; IMR SA, 18.26 [P=0.1])

50 percutaneous coronary intervention with both NSTEMI (11.0% versus 7.8%, P=0.04) and STEMI (22.6% vers

51 d underwent revascularization less commonly (NSTEMI: 55.6% versus 63.6%, P<0.001; STEMI: 87.3% versus

52 .001; activities of daily living disability, NSTEMI: 19.7% versus 11.4%, P<0.001; STEMI: 14.8% versus

53 lower rates of obstructive coronary disease (NSTEMI: P<0.001; STEMI: P=0.02), driven by lower rates o

54 vation (STEMI) and non-ST-segment elevation (NSTEMI) MI.

55 CREB activity and silencing PTPN22 enhanced NSTEMI patients' ability to generate Treg.

56 hs-cTnT change may not be useful to exclude NSTEMI, particularly as these patients show both short-t

57 n-ST-Elevation Myocardial Infarction (FAMOUS-NSTEMI) study (NCT01764334) has recently demonstrated th

58 k factors, and medications, the age of first NSTEMI occurred 3.5, 6.8, 9.4, and 12.0 years earlier wi

59 The mean patient ages (+/- SD) of first NSTEMI were 74.6 +/- 14.3 years and 58.7 +/- 12.5 years

60 y mass index (BMI) with patient age of first NSTEMI.

61 ionship between BMI and earlier age of first NSTEMI.

62 xcess adiposity is strongly related to first NSTEMI occurring prematurely.

63 For NSTEMI patients, a lower HDL-C was associated with a hig

64 For NSTEMI, the analogous odds ratios were 1.81, 2.41, 3.50,

65 (10.9%) and traditional Medicare (11.1%) for NSTEMI (difference, -0.2 percentage points [95% CI, -0.4

66 95% CI, -2.2 to -0.7] and 12.0% vs 12.5% for NSTEMI; difference, -0.5 percentage points [95% CI, -0.9

67 which enhances baseline risk assessment for NSTEMI care.

68 - vs high-income strata were similar but for NSTEMI were generally 1 to 2 percentage points higher am

69 er for females than males in 5 countries for NSTEMI.

70 ments are the preferred test to evaluate for NSTEMI.

71 ountries and years with similar findings for NSTEMI.

72 tive and absolute reductions were larger for NSTEMI, with 1267 admissions per week in 2019 and 733 pe

73 s to be safely and immediately ruled out for NSTEMI.

74 699 (77.8%) with 2784 nonculprit lesions had NSTEMI.

75 in both AMI subgroups (cognitive impairment, NSTEMI: 20.6% versus 14.3%, P<0.001; STEMI: 20.6% versus

76 ce in IMR pre-PCI between NSTEMI and SA (IMR NSTEMI, 22.73; IMR SA, 18.26 [P=0.1]).

77 h SA and NSTEMI (IMR STEMI, 36.51 versus IMR NSTEMI, 22.73 [P=0.01] versus IMR SA, 18.26 [P<0.0001]).

78 In NSTEMI, a lower LDL-C was paradoxically associated with

79 m(2) (interquartile range, 5.3-5.6 mm(2)) in NSTEMI (P=0.99).

80 compared with conventional PCI (n = 219) in NSTEMI patients with thrombus-containing lesions.

81 17.7 mm (interquartile range, 17.1-18.4) in NSTEMI (P=0.63), and the median minimal lumen area was 5

82 yrosine 292, enhancing T-cell activation, in NSTEMI helper T cells versus SA and controls (each, p <

83 of at least 3x upper reference limit and in NSTEMI as a pre-PCI troponin T fall, followed by post-PC

84 e response element-binding protein (CREB) in NSTEMI (p < 0.05 vs. controls), which recovered at 1 yea

85 IMI score was good in STEMI but only fair in NSTEMI.

86 Finally, in NSTEMI patients, helper T cells had a reduced ability in

87 the primary outcome was marginally higher in NSTEMI vs STEMI patients (adjusted HR: 1.19; 95% CI: 1.0

88 underlying pathophysiological mechanisms in NSTEMI and STEMI.

89 k of recurrent MI and all-cause mortality in NSTEMI patients, when compared to conservative managemen

90 ratio, 1.42 [95% CI, 1.24-1.64]) but not in NSTEMI (adjusted odds ratio, 0.97 [95% CI, 0.83-1.13]).

91 to conservative management were observed in NSTEMI patients without frailty.

92 tion thrombectomy in conjunction with PCI in NSTEMI with a thrombus-containing lesion does not lead t

93 f the microcirculation would be preserved in NSTEMI.

94 tients (72.8%) to either rule out or rule in NSTEMI, leaving 564 patients (27.2%) in the observe-zone

95 Similarly, in NSTEMI (Non-ST Segment Elevation) patients, TNFalpha is

96 n with oral losmapimod was well tolerated in NSTEMI patients and might improve outcomes after acute c

97 ted OR, 1.15; 95% CI, 1.06-1.24), whereas in NSTEMI (adjusted OR, 0.77; 95% CI, 0.63-0.95) and unstab

98 -ST-segment-elevation myocardial infarction (NSTEMI) and GRACE (Global Registry of Acute Coronary Eve

99 -ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (

100 -ST-segment elevation myocardial infarction (NSTEMI) and to see if WBC count was a significant predic

101 -ST-segment elevation myocardial infarction (NSTEMI) can provide an estimate of a patient's prognosis

102 -ST-segment elevation myocardial infarction (NSTEMI) in a double-blind, randomised, placebo-controlle

103 -ST-segment-elevation myocardial infarction (NSTEMI) is a controversial issue.

104 -ST-segment elevation myocardial infarction (NSTEMI) is associated with increased risk of bleeding in

105 -ST-segment-elevation myocardial infarction (NSTEMI) management has evolved considerably over the pas

106 -ST-segment elevation myocardial infarction (NSTEMI) or recent ST-segment elevation myocardial infarc

107 -ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (S

108 -ST-segment elevation myocardial infarction (NSTEMI) patients treated by percutaneous coronary interv

109 -ST-segment elevation myocardial infarction (NSTEMI) patients.

110 -ST-segment elevation myocardial infarction (NSTEMI) patients.

111 -ST-segment-elevation myocardial infarction (NSTEMI) reduce ischemic events but increase bleeding.

112 (UA)/non-ST-elevation myocardial infarction (NSTEMI) that were conducted nearly a decade apart but wi

113 -ST-segment-elevation myocardial infarction (NSTEMI) using intravascular ultrasound.

114 -ST-segment elevation myocardial infarction (NSTEMI) yields improved outcomes compared with a conserv

115 -ST-segment elevation myocardial infarction (NSTEMI), 20 with stable angina (SA), and 20 controls.

116 -ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction

117 -ST-segment-elevation myocardial infarction (NSTEMI), and unstable angina (UA).

118 with non-ST elevation myocardial infarction (NSTEMI), but the trials excluded very elderly patients.

119 -ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), cor

120 -ST-segment elevation myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin

121 -ST-segment elevation myocardial infarction (NSTEMI), whereas patients <65 years of age presented alm

122 -ST-segment elevation myocardial infarction (NSTEMI).

123 -ST-segment-elevation myocardial infarction (NSTEMI).

124 -ST-segment elevation myocardial infarction (NSTEMI).

125 -ST-segment elevation myocardial infarction (NSTEMI).

126 -ST-segment elevation myocardial infarction (NSTEMI).

127 -ST-segment elevation myocardial infarction (NSTEMI).

128 with non-ST elevation myocardial infarction (NSTEMI).

129 -ST-segment elevation myocardial infarction (NSTEMI).

130 wing non-ST-elevation myocardial infarction (NSTEMI).

131 -ST-segment elevation myocardial infarction (NSTEMI).

132 -ST-segment elevation myocardial infarction (NSTEMI).

133 -ST-segment elevation myocardial infarction (NSTEMI)/unstable angina (UA) who were managed medically

134 -ST-segment elevation myocardial infarction [NSTEMI] cases) underwent PCI.

135 ssel Non ST Elevation Myocardial Infarction [NSTEMI] PATIENTS: One Stage Versus Multistaged Percutane

136 ificantly underused in the medically managed NSTEMI population and demonstrates wide variability by h

137 sample, women were slightly older than men (NSTEMI: 82.1 versus 81.3, P<0.001; STEMI: 82.2 versus 80

138 93 with non-ST-segment elevation [acute] MI (NSTEMI) presenting to US hospitals from 2009-2018.

139 n patients with non-ST-segment-elevation MI (NSTEMI) after percutaneous coronary intervention (PCI).

140 PCI) for either non-ST segment elevation MI (NSTEMI) or stable angina.

141 r patients with non-ST segment elevation MI (NSTEMI) overall, the adjusted odds of mortality and nonh

142 MI) and 933 755 non-ST-segment-elevation MI (NSTEMI) patients at 1230 hospitals from 2009 to 2018 wer

143 lore all MI and non-ST-segment-elevation MI (NSTEMI) versus ST-segment-elevation MI (STEMI) over time

144 especially in cases of non-ST elevation MI (NSTEMI), since these cases are not readily identified by

145 (STEMI) versus non-ST-segment elevation MI (NSTEMI).

146 ion (STEMI) and non-ST-segment elevation MI (NSTEMI).

147 MI (STEMI) and non-ST-segment elevation MI (NSTEMI).

148 rction [MI]; very small non-ST-elevation MI [NSTEMI] had peak troponin level <0.5 mug/L).

149 [STEMI] versus non-ST-segment-elevation MI [NSTEMI]) might shed light on the potential mechanisms.

150 ssociated with increased risks for total MI, NSTEMI, and STEMI, with ORs of 1.077 (95% CI: 1.037-1.12

151 associated with increased risks of total MI, NSTEMI, and STEMI, with ORs of 1.099 (95% CI: 1.057-1.14

152 6.4%, P<0.001; impaired functional mobility, NSTEMI: 44.5% versus 30.7%, P<0.001; STEMI: 39.4% versus

153 STEMI (26.2% versus 15.6%, P<0.001) but not NSTEMI (17.8% versus 15.7%, P=0.21).

154 her improvement, particularly in the care of NSTEMI patients.

155 mon in patients with a clinical diagnosis of NSTEMI in our hospital, a small hs-cTnT change may not b

156 in 1,178 patients with a final diagnosis of NSTEMI presenting <24 h after symptom onset.

157 nT) levels are required for the diagnosis of NSTEMI, according to the new universal definition of acu

158 e to hs-cTn values in the early diagnosis of NSTEMI, improving diagnostic discrimination and enabling

159 cTnT was not mandatory for the diagnosis of NSTEMI, serial samples of cTnT were measured with a high

160 Early identification of NSTEMI patients who are at high risk of in-hospital mort

161 ischemic risk prediction for optimization of NSTEMI care; however, existing models are not well suite

162 Proportions of NSTEMI codes increased remarkably in both the primary an

163 vasoreactivity is blunted in the setting of NSTEMI, this is a reflection of the greater volume of at

164 In this randomized clinical trial of NSTEMI in frail older patients, there was no benefit to

165 ed 16,365 patients with incident UA (35%) or NSTEMI (65%); 36% of these patients were prescribed clop

166 unclassifiable MI group with either STEMI or NSTEMI did not change this conclusion.

167 ure in the subsequent 5 years after STEMI or NSTEMI, even after accounting for differences in angiogr

168 ior clopidogrel use who presented with UA or NSTEMI between 2003 and 2008 and were medically managed

169 d September 2003, 56,352 patients with UA or NSTEMI were treated at 310 US hospitals participating in

170 ity in medically managed patients with UA or NSTEMI, the effectiveness of clopidogrel in actual clini

171 ge (<4 ng/L) is necessary to safely rule out NSTEMI in patients remaining in the observe-zone of the

172 eria for the observe-zone patients ruled out NSTEMI with a 3h hs-cTnT concentration <15 ng/L and a 0/

173 P<0.0001) and compared with NSTEMI patients (NSTEMI, 2.46; P</=0.001).

174 Among 5639 eligible patients, NSTEMI was the adjudicated final diagnosis in 1051 (18.6

175 ny reperfusion (STEMI) or revascularization (NSTEMI), and had higher rates of bleeding.

176 Among patients with STEMI or very-high-risk NSTEMI and multivessel coronary artery disease, FFR-guid

177 In patients with high-risk NSTEMI, undergoing CAG within the initial 12 hours after

178 Compared with STEMI shock, NSTEMI shock was more likely in patients who were older

179 for older adults with hemodynamically stable NSTEMI and outcomes associated with ICU utilization amon

180 ents with STEMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing prim

181 myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment

182 (STEMI), 14 466 (29% women) with non-STEMI (NSTEMI), and 19 777 (40% women) with unstable angina.

183 on myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina.

184 on myocardial infarction (STEMI), non-STEMI (NSTEMI), myocardial infarction of unknown type, or other

185 cardial infarction (STEMI) versus non-STEMI (NSTEMI).

186 myocardial infarction [STEMI] and non-STEMI [NSTEMI]) and subsequently evaluated for sex-based differ

187 studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) included 1235 study participants w

188 ) (AIDA STEMI n = 759) and non-STEMI (TATORT-NSTEMI n = 336) were analysed fully automated and manual

189 The TATORT-NSTEMI (Thrombus Aspiration in Thrombus Containing Culpr

190 n the STEMI cohort was 31.2% and 8.5% in the NSTEMI cohort of the PCI subpopulation.

191 otein cholesterol were more prevalent in the NSTEMI group.

192 Women in the NSTEMI subgroup presented less frequently with chest pai

193 nd the absolute change <9 ng/l in 12% of the NSTEMI patients.

194 However, this association is limited to NSTEMI.

195 pital major bleeding among community-treated NSTEMI patients enrolled in the Can Rapid risk stratific

196 ing was seen (elective PCI: 1.4% to 1.1%; UA/NSTEMI: 2.3% to 1.8; STEMI: 4.9% to 4.5%).

197 patients with elective PCI (n = 599,524), UA/NSTEMI (n = 836,103), and STEMI (n = 267,632).

198 gnificantly higher mortality 1 year after UA/NSTEMI (hazard ratio [HR], 1.65; 95% CI, 1.30-2.10) or S

199 ciated with higher 30-day mortality after UA/NSTEMI (odds ratio [OR], 1.78; 95% confidence interval [

200 patients who were medically managed after UA/NSTEMI, clopidogrel use was associated with a lower risk

201 se of FFR has not been investigated after UA/NSTEMI.

202 4% for elective PCI, and 5.7% to 2.8% for UA/NSTEMI (both p <0.001).

203 ocardial Infarction (TIMI) risk score for UA/NSTEMI is an integrated approach that uses baseline vari

204 year reduction in annual bleeding risk in UA/NSTEMI and elective PCI, but not in STEMI.

205 ve approach should be used more widely in UA/NSTEMI patients, particularly those at high risk.

206 benefits of an early invasive strategy in UA/NSTEMI.

207 a/non-ST-elevation myocardial infarction (UA/NSTEMI) is a common but heterogeneous disorder with pati

208 -segment elevation myocardial infarction (UA/NSTEMI) treated with the platelet glycoprotein (Gp IIb/I

209 -segment elevation myocardial infarction (UA/NSTEMI).

210 -segment elevation myocardial infarction (UA/NSTEMI).

211 -segment elevation myocardial infarction (UA/NSTEMI).

212 -segment elevation myocardial infarction (UA/NSTEMI).

213 ntaneous MI following a medically managed UA/NSTEMI event is common.

214 term natural history of medically managed UA/NSTEMI patients and could be used to optimize risk strat

215 ent elevation myocardial infarction (MI) (UA/NSTEMI) present with a wide spectrum of risk for death a

216 ch may aid the initial risk assessment of UA/NSTEMI, especially in women.

217 been validated in several other trials of UA/NSTEMI.

218 Seventy patients who had recent UA/NSTEMI and an intermediate single-vessel stenosis were r

219 1) the use of FFR in patients with recent UA/NSTEMI markedly reduces the duration and cost of hospita

220 rsus a conservative strategy in high-risk UA/NSTEMI patients treated with GP IIb/IIIa inhibition.

221 nd 15,459 with unstable angina/non-STEMI [UA/NSTEMI]), of whom 10 613 (17.1%) had diabetes.

222 tes than without diabetes presenting with UA/NSTEMI (2.1% vs 1.1%, P < .001) and STEMI (8.5% vs 5.4%,

223 Of the 2,220 patients with UA/NSTEMI enrolled in the Treat Angina with Aggrastat and D

224 ive the score was the 2,220 patients with UA/NSTEMI enrolled in the Treat Angina with Aggrastat and D

225 S, patients with diabetes presenting with UA/NSTEMI had a risk of death that approached patients with

226 In patients with UA/NSTEMI treated with the Gp IIb/IIIa inhibitor tirofiban,

227 A total of 1957 patients with UA/NSTEMI were assigned to receive unfractionated heparin (

228 Among patients with UA/NSTEMI, a novel risk score based on admission clinical v

229 Among patients with UA/NSTEMI, elevated BNP levels are associated with tighter

230 conclusions: In patients with UA/NSTEMI, elevations in a simple, widely available blood t

231 Advances in the care of patients with UA/NSTEMI, including glycoprotein IIb/IIIa inhibition and s

232 In patients with UA/NSTEMI, the TIMI risk score is a simple prognostication

233 In patients with UA/NSTEMI, there was a different pattern of presenting biom

234 igh-risk plaques was similar in STEMI versus NSTEMI (38.8% versus 32.7%; P=0.11).

235 rable plaques was comparable in STEMI versus NSTEMI, as was the overall long-term incidence of noncul

236 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial.

237 are patients 65 years or older admitted with NSTEMI to 346 hospitals participating in the Acute Coron

238 In older adults with NSTEMI, an invasive strategy did not result in a signifi

239 However, AF was associated with NSTEMI (hazard ratio, 1.80; 95% confidence interval, 1.3

240 nonculprit, 2.9; P<0.0001) and compared with NSTEMI patients (NSTEMI, 2.46; P</=0.001).

241 n) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treat

242 roponin measurements and were diagnosed with NSTEMI between 2010 (2008 for University College Hospita

243 ible patients, 854 (18%) were diagnosed with NSTEMI.

244 Overall mortality in the group with NSTEMI was higher (10.9%) than patients with STEMI treat

245 Among patients hospitalized with NSTEMI in England and Wales, improvements in all-cause m

246 Black individuals with NSTEMI experienced a clinically insignificant 7% greater

247 ional Registry of Myocardial Infarction with NSTEMI.

248 verestimated risk for ethnic minorities with NSTEMI.

249 ival of patients aged 80 years or older with NSTEMI.

250 el may be preserved in selected patents with NSTEMI.

251 (95% CI, 96.0-99.9), missing 1 patient with NSTEMI.

252 and declined significantly in patients with NSTEMI (1.9%-1.3%, P=0.0001).

253 in patients with STEMI than in patients with NSTEMI (12.8% versus 10.1%; P=0.03).

254 P value <0.0001) compared with patients with NSTEMI (40.8% shock versus 2.3% no shock, odds ratio, 19

255 Among 389057 patients with NSTEMI (median age, 72.7 years [IQR, 61.7-81.2 years]; 6

256 n, 9.4%, versus men, 4.5%) and patients with NSTEMI (women, 4.7%, versus men, 2.9%).

257 Of 28018 patients with NSTEMI 65 years or older (median age, 77 years [interqua

258 me With Otamixaban) randomized patients with NSTEMI and CAG scheduled within 72 hours to heparin plus

259 Patients with NSTEMI and multivessel disease who had successful revasc

260 til 2015, whereas mortality in patients with NSTEMI appears stable since 2010.

261 omy on microvascular injury in patients with NSTEMI compared with standard percutaneous coronary inte

262 Patients with NSTEMI demonstrated greater segmental percent atheroma v

263 rescription rates among 23 186 patients with NSTEMI discharged from 382 US hospitals between October

264 Consecutive patients with NSTEMI from January 2017 to April 2022 undergoing PCI wi

265 Data on patients with NSTEMI in 247 hospitals in England and Wales were obtain

266 nting with shock at admission, patients with NSTEMI presenting with shock had longer delays to percut

267 the sample, 54.9% of eligible patients with NSTEMI received clopidogrel prescription at hospital dis

268 are, or outcomes among 145,357 patients with NSTEMI treated between January 1, 2001, and December 31,

269 Hospitals with high (>70% of patients with NSTEMI treated in an ICU during the index hospitalizatio

270 The proportion of patients with NSTEMI treated in the ICU varied across hospitals (media

271 ade about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission.

272 chemic events were frequent in patients with NSTEMI undergoing PCI with prognostic implications.

273 Among 1412 patients with NSTEMI undergoing PCI with stable or falling cTnI levels

274 ilization of the ICU for older patients with NSTEMI varied significantly among hospitals.

275 Patients with NSTEMI were included and divided into a non-frailty grou

276 A total of 111,847 patients with NSTEMI were included in the final analysis.

277 e coronary microcirculation in patients with NSTEMI when compared with a model of preserved microcirc

278 anagement appears to extend to patients with NSTEMI who are aged 80 years or older.

279 y involving 40,616 consecutive patients with NSTEMI who received fondaparinux or LMWH between Septemb

280 tween the TRI and mortality in patients with NSTEMI with a >30-fold difference in mortality rates bet

281 and delayed (>24 hours) CAG in patients with NSTEMI with GRACE score >140 with ischemic outcomes.

282 Of the 1976 patients with NSTEMI, 101 died within 3 days of their peak troponin co

283 In routine clinical care of patients with NSTEMI, fondaparinux was associated with lower odds than

284 In patients with NSTEMI, percutaneous coronary intervention </=72 hours f

285 Among patients with NSTEMI, percutaneous coronary intervention use increased

286 ined stable (68+/-14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hyperten

287 with reperfusion therapy or in patients with NSTEMI, whether or not they were treated with percutaneo

288 ents with STEMI versus 4.3% of patients with NSTEMI.

289 ation is preserved in selected patients with NSTEMI.

290 presenting with shock than in patients with NSTEMI.

291 p between TRI and mortality in patients with NSTEMI.

292 ratification and management of patients with NSTEMI.

293 and declined significantly for patients with NSTEMI.

294 9% in 2010 and 6.3% in 2015 in patients with NSTEMI.

295 ath and MI, particularly among patients with NSTEMI.

296 e higher-risk profile of the population with NSTEMI.

297 nificant only among patients presenting with NSTEMI (HR: 0.67; CI: 0.59 to 0.76; pint < 0.01), not am

298 Patients presenting with NSTEMI are increasing compared to STEMI and constitute a

299 th shock, particularly those presenting with NSTEMI.

300 t between patients with STEMI and those with NSTEMI and across other major subgroups.